Compare Dr. Reddys with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs FRESENIUS KABI ONCO. - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB FRESENIUS KABI ONCO. DR. REDDYS LAB/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 21.6 22.1 97.5% View Chart
P/BV x 3.2 3.1 103.7% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DR. REDDYS LAB   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
FRESENIUS KABI ONCO.
Mar-13
DR. REDDYS LAB/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs2,875176 1,633.5%   
Low Rs1,88879 2,405.1%   
Sales per share (Unadj.) Rs930.237.7 2,468.4%  
Earnings per share (Unadj.) Rs117.45.1 2,305.4%  
Cash flow per share (Unadj.) Rs185.86.7 2,762.9%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs844.442.5 1,984.8%  
Shares outstanding (eoy) m166.07158.23 105.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.63.4 75.8%   
Avg P/E ratio x20.325.0 81.2%  
P/CF ratio (eoy) x12.818.9 67.7%  
Price / Book Value ratio x2.83.0 94.3%  
Dividend payout %17.00-   
Avg Mkt Cap Rs m395,49620,135 1,964.2%   
No. of employees `00022.01.2 1,906.8%   
Total wages/salary Rs m33,562703 4,772.8%   
Avg. sales/employee Rs Th7,032.85,176.2 135.9%   
Avg. wages/employee Rs Th1,527.9610.4 250.3%   
Avg. net profit/employee Rs Th887.7699.6 126.9%   
INCOME DATA
Net Sales Rs m154,4825,963 2,590.7%  
Other income Rs m3,37518 18,750.0%   
Total revenues Rs m157,8575,981 2,639.3%   
Gross profit Rs m31,7821,430 2,222.4%  
Depreciation Rs m11,348258 4,400.2%   
Interest Rs m889-26 -3,419.2%   
Profit before tax Rs m22,9201,216 1,884.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m3,858342 1,127.4%   
Profit after tax Rs m19,500806 2,419.7%  
Gross profit margin %20.624.0 85.8%  
Effective tax rate %16.828.1 59.8%   
Net profit margin %12.613.5 93.4%  
BALANCE SHEET DATA
Current assets Rs m111,1015,102 2,177.8%   
Current liabilities Rs m58,9732,385 2,472.2%   
Net working cap to sales %33.745.6 74.1%  
Current ratio x1.92.1 88.1%  
Inventory Days Days79150 52.9%  
Debtors Days Days94113 83.2%  
Net fixed assets Rs m101,2455,148 1,966.6%   
Share capital Rs m830158 524.7%   
"Free" reserves Rs m139,4066,556 2,126.5%   
Net worth Rs m140,2366,732 2,083.2%   
Long term debt Rs m22,000952 2,310.4%   
Total assets Rs m224,65610,388 2,162.6%  
Interest coverage x26.8-45.8 -58.5%   
Debt to equity ratio x0.20.1 110.9%  
Sales to assets ratio x0.70.6 119.8%   
Return on assets %9.17.5 120.9%  
Return on equity %13.912.0 116.2%  
Return on capital %14.914.6 102.3%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m88,6735,298 1,673.8%   
Fx outflow Rs m19,1041,772 1,078.0%   
Net fx Rs m69,5693,525 1,973.4%   
CASH FLOW
From Operations Rs m28,7041,274 2,252.9%  
From Investments Rs m-7,727-1,204 641.7%  
From Financial Activity Rs m-21,326-196 10,875.1%  
Net Cashflow Rs m-314-126 248.6%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 5.4 0.3 1,800.0%  
FIIs % 35.3 9.6 367.7%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 9.1 168.1%  
Shareholders   75,885 42,599 178.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   PFIZER  ABBOTT INDIA  PANACEA BIOTECH  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strengthening Rupee, Inflation & Factory Output Data, and Top Stocks in Action Today(Pre-Open)

On Friday, Indian share markets witnessed most of the buying interest during closing hours and ended on a strong note.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 13, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS